Castrate Resistant Prostate Cancer Therapeutics Market Size
| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Historical Data Period | 2019 - 2023 |
| CAGR | 6.50% |
| Fastest Growing Market | North America |
| Largest Market | Asia Pacific |
Major Players*Disclaimer: Major Players sorted in no particular order |
Castrate Resistant Prostate Cancer Therapeutics Market Analysis
The Castrate Resistant Prostate Cancer Therapeutics Market is expected to register a CAGR of 6.5% during the forecast period.
Furthermore, growing adoption of novel drugs, along with an unhealthy lifestyle are key factors anticipated to accelerate market growth. The need for faster treatment options and investments in R&D by key players is also fueling the growth rate of the market.
According to a researh article by Nicolas H Thurin et al., published in Cancer epidemiology 2020, the prevalence and incidence of metastatic castration-resistant prostate cancer (mCRPC) in France were estimated as 62 and 21 cases per 100,000 population. In addition, maximum metastatic castration-resistant prostate cancer (mCRPC) incidence was in men who were aged 80-89 (175 per 100,000 population). Thus, owing to above mentioned factors it is expected to drive market growth over the forecast period.
Castrate Resistant Prostate Cancer Therapeutics Market Trends
Hormonal Therapy Segment is Expected to Hold a Significant Market Share over the Forecast Period.
The major factors driving the growth of the segment include rising geriatric population who are more prone to castrate resistant prostate cancer, launch of new drugs, presence of high number of approved drugs and the expansion of product indication. In addition, the rising development of innovative drugs to address unmet needs and current treatment options is expected to boost the growth of the market for castrate-resistant prostate cancer.
According to a National Clinical Trial (NCT) Registry, Sir Mortimer B. Davis Jewish General Hospital is currently conducting a phase II clinical trial with a new generation of hormonal therapy Darolutamide to assess the response of stereotactic body radiation therapy (SBRT) layered on Darolutamide (BAY1841788) on radiological progression-free survival (RPFS) and deferring palliative second line systemic therapy in patients with castration resistant prostate cancer. The trial began in October 2020 and expected to complete in November 2027.
Thus, increasing research and development activities along with rising prevalence of castrate resistant prostate cancer due to aging population is expected to drive the market growth.
North America Region is Expected to Hold a Major Market Share Over the Forecast Period
In North America region, the United States is expected to hold signifcant market share due to high prevalence of the disease, the presence of major market players, increasing research and development activities and favorable reimbursement policies.
In June 2020, in United States, Exelixis, Inc in collaboration with Roche-Genentech and Takeda initiated a phase III clinical trial to evaluate the safety and efficacy of cabozantinib in combination with atezolizumab in men with metastatic castration-resistant prostate cancer (mCRPC).
Furthermore, presence of favorable reimbursement policies for patients is expected to boost the growth of the market for castrate-resistant prostate cancer. For instance, Jevtana is covered under Medicare Part B benefits. It is identified by J9043 and C9276 under Healthcare Common Procedure Coding System. Thus, owing to above mentioned factors, market in the United States is expected to be one of the largest and is also expected to grow in the future.
Castrate Resistant Prostate Cancer Therapeutics Industry Overview
The Castrate Resistant Prostate Cancer Therapeutics Market is consolidated competitive and consists of few major players. In terms of market share, few of the major players currently dominate the market. Some of the market players include Sanofi, Johnson & Johnson, Pfizer, Inc, Bayer AG, Dendreon Pharmaceuticals LLC and others.
Castrate Resistant Prostate Cancer Therapeutics Market Leaders
-
Sanofi
-
Johnson & Johnson
-
Bayer AG
-
Dendreon Pharmaceuticals LLC
-
Pfizer Inc
- *Disclaimer: Major Players sorted in no particular order
Castrate Resistant Prostate Cancer Therapeutics Industry Segmentation
As per scope of the report, castration-resistant prostate cancer is a disease progression which may be due to rise in serum prostate-specific antigen, progression of pre-existing disease, and appearance of new metastases. The Castrate Resistant Prostate Cancer Therapeutics Market is segmented by treatment type and geography.
| By Treatment Type | Chemotherapy | ||
| Hormonal Therapy | |||
| Radiation Therapy | |||
| Other Treatment Types | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle-East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Chemotherapy |
| Hormonal Therapy |
| Radiation Therapy |
| Other Treatment Types |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle-East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Castrate Resistant Prostate Cancer Therapeutics Market Research FAQs
What is the current Castrate Resistant Prostate Cancer Therapeutics Market size?
The Castrate Resistant Prostate Cancer Therapeutics Market is projected to register a CAGR of 6.5% during the forecast period (2025-2030)
Who are the key players in Castrate Resistant Prostate Cancer Therapeutics Market?
Sanofi, Johnson & Johnson, Bayer AG, Dendreon Pharmaceuticals LLC and Pfizer Inc are the major companies operating in the Castrate Resistant Prostate Cancer Therapeutics Market.
Which is the fastest growing region in Castrate Resistant Prostate Cancer Therapeutics Market?
North America is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Castrate Resistant Prostate Cancer Therapeutics Market?
In 2025, the Asia Pacific accounts for the largest market share in Castrate Resistant Prostate Cancer Therapeutics Market.
What years does this Castrate Resistant Prostate Cancer Therapeutics Market cover?
The report covers the Castrate Resistant Prostate Cancer Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Castrate Resistant Prostate Cancer Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Castrate-Resistant Prostate Cancer Industry Report
Statistics for the 2025 Castrate Resistant Prostate Cancer Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Castrate Resistant Prostate Cancer Therapeutics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
